116 Pathologic Predictors of Response to Neoadjuvant Anti-HER2 Therapy in ER+/HER2+ Breast Carcinomas: Time for HER2-High and HER2-Medium Categories?

View at publisher Summarise with VIRAT
Authors: Wenli Dai, Beth Z. Clark, Jeffrey L. Fine, Rohit Bhargava, Jing Yu
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Fields of Study & Subjects

HER2/EGFR in Cancer Research Breast Cancer Treatment Studies Gastric Cancer Management and Outcomes

Publication details

Journal / source
Laboratory Investigation
Volume
106
Issue
3
Pages
104395–104395
Publication date
1 March 2026
Language
EN